ACM
QNRX

ADAR1 Capital Management’s Quoin Pharmaceuticals QNRX Stock Holding History

ADAR1 Capital Management’s Portfolio QNRX Stock Details QNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-58,230
Closed -$840K – 335
2025
Q4 		$840K Buy
+58,230
New +$793K 0.06% 146

Other funds holding QNRX

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
CC
Centiva Capital New York $13.6B AUM 20% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

ADAR1 Capital Management's QNRX Position: Q1 2026 in Review

ADAR1 Capital Management sold out of Quoin Pharmaceuticals (QNRX) in Q1 2026, closing a stake of 58,230 shares — an estimated $840K sold.

ADAR1 Capital Management first reported a position in QNRX in Q4 2025 and held it in 1 quarter. The position peaked at $840K in Q4 2025. 22 funds tracked by Wall St. Rank hold QNRX as of Q1 2026.

  • ADAR1 Capital Management reported no remaining Quoin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 58,230 Quoin Pharmaceuticals shares in Q1 2026, an estimated $840K.
  • ADAR1 Capital Management first reported a position in Quoin Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • ADAR1 Capital Management's Quoin Pharmaceuticals position peaked at $840K in Q4 2025.
  • 22 funds tracked by Wall St. Rank held Quoin Pharmaceuticals as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.